- CGuardTM
- PI: Joachim Schofer; Co-PI: Piotr Musialek
- 30 carotid artery stenting patients
- Prospective, multi-center, international, open label, single arm, non-randomized
- Primary endpoint: 30 day MACE (death, stroke, MI)
- Follow up: 6 months
Clinical Trials
CARENET 30d
PARADIGM 101
- CGuard™
- PI: Piotr Musialek
- 101 all comers, symptomatic and high-risk asymptomatic patients
- A prospective, all-referral-study
- Follow up: 0-1 month, 1-12 months
CASANA
- CGuard™
- PI: Renato Casana
- 82 consecutive patients
- A single centre study
- Follow up: 30 day results
WISSGOTT
- CGuard™
- PI: Christian Wissgott and Reimer Andresen
- 30 Consecutive patients
- Prospective single-center study
- Follow up: 6 months
WISSGOTT One size- fits-all
- CGuard™
- PI: Christian Wissgott
- 30 Consecutive patients
- Prospective, single-center study
- Follow up: 6 months
IRON-GUARD 1
- CGuard™
- PI: Carlo Setacci and Francesco Speziale
- 200 patients in 12 centers
- Physician-initiated prospective multicenter study
- Follow up: 30 days and 12 months
IRON-GUARD 2
- CGuard™
- PI: Francesco Speziale
- A Real life Registry, Physician-initiated prospective multicenter study
- 733 patients in 20 enrolling centers
- Follow up: 30 days, 12 months
PARADIGM-EXTEND
- CGuard™
- PI: Piotr Musialek
- A prospective, all-referral-study
- 428 (from 550 expected) all comers, high risk patients
- Follow up: 0-1 month, 1-12 months, 12-24 months, 24-36 months, 48-60 months
SIBERIA TRIAL
- CGuard™
- PI: Andrey Karpenko
- Prospective 1:1 randomized controlled study
- Designed and executed to obtain level 1 evidence
- Independent Investigator Initiated Study
- Single center
- Randomized comparison of two interventional arms.
- 100 consecutive unselected patients (50 Acculink™ and 50 CGuard™)
